Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Otten

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 22, 2023
Structured Multidisciplinary Follow-Up After Pediatric Intensive Care: A Model for Continuous Data-Driven Health Care InnovationEleonore S V de Sonnaville, Job B M van Woensel, Johannes B van Goudoever, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Arthritis Research & Therapy|August 8, 2015
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Lisette W A Van Suijlekom-Smit, Marieke H Otten, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2022
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter studyS L Groenland, R A G van Eerden, K Westerdijk, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 22, 2023
Structured Multidisciplinary Follow-Up After Pediatric Intensive Care: A Model for Continuous Data-Driven Health Care InnovationEleonore S V de Sonnaville, Job B M van Woensel, Johannes B van Goudoever, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Arthritis Research & Therapy|August 8, 2015
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Lisette W A Van Suijlekom-Smit, Marieke H Otten, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2022
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter studyS L Groenland, R A G van Eerden, K Westerdijk, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Pageof 12